Psychiatry · Clinical trials
Social Anxiety Disorder Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About social anxiety disorder — and why its trials are hard
Social Anxiety Disorder (social phobia) is characterized by intense, persistent fear of social or performance situations in which the person anticipates scrutiny, embarrassment, or humiliation, leading to avoidance and functional impairment. It is one of the most common anxiety disorders and responds to both SSRIs/SNRIs and cognitive-behavioral therapy. Several agents carry FDA approval for the generalized form: paroxetine (1999), sertraline (2003), and extended-release venlafaxine (2003), with fluvoxamine CR later approved. The Liebowitz Social Anxiety Scale (LSAS) is the standard primary endpoint, supported by CGI-I responder rates. Approved drugs reduce LSAS scores meaningfully and roughly double placebo response rates, though partial response and relapse after discontinuation are common. Beta-blockers and benzodiazepines are used off-label, particularly for performance anxiety. Recent innovation has targeted rapid, as-needed acute treatment: the investigational neuroactive nasal spray fasedienol (PH94B) produced mixed Phase 3 results, meeting the LSAS/SUDS endpoint in some studies but failing in others, illustrating the difficulty of demonstrating consistent acute anxiolytic efficacy.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Paroxetine (Paxil) | 1999 | Adults with generalized social anxiety disorder; oral SSRI | 12-week placebo-controlled trials (Stein et al. 1998, JAMA) | LSAS total score and CGI-I responder rate change from baseline | Responder rates roughly 55% vs ~24% placebo on CGI-I; significant LSAS reduction (unverified exact figures) |
| Sertraline (Zoloft) | 2003 | Adults with generalized social anxiety disorder; oral SSRI | 20-week placebo-controlled trials (Van Ameringen et al. 2001; Liebowitz et al.) | LSAS total score and CGI-I responder rate change from baseline | Significant LSAS improvement vs placebo; responder rates approximately 40-55% vs placebo (unverified exact figures) |
| Venlafaxine extended-release (Effexor XR) | 2003 | Adults with generalized social anxiety disorder; SNRI | 12-week placebo-controlled trials (Rickels et al.; Liebowitz et al. 2005) | LSAS total score and CGI-I responder rate change from baseline | Significant LSAS reduction vs placebo; efficacy comparable to SSRIs (unverified exact figures) |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in social anxiety disorder development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Fasedienol (PH94B) nasal spray — PALISADE-1 (2023) and PALISADE-4 (2026) Phase 3 public-speaking / acute treatment studies; endpoint change in SUDS/LSAS during a social challenge | PALISADE-1 failed to meet its primary endpoint and PALISADE-4 (2026) also failed, though PALISADE-2 and PALISADE-3 were positive; overall inconsistent acute efficacy | High placebo response in acute-challenge paradigms, variability across sites, and difficulty demonstrating reproducible rapid anxiolysis |
Choosing the right endpoint
Primary endpoints that matter in social anxiety disorder trials
- LSAS (Liebowitz Social Anxiety Scale) — 24-item clinician-rated fear and avoidance scale; standard primary endpoint for generalized SAD
- CGI-I responder rate — Global clinician-rated improvement; common co-primary/key secondary defining response
- SUDS (Subjective Units of Distress Scale) — Used as the acute endpoint in as-needed/challenge-paradigm trials such as PALISADE
- SDS (Sheehan Disability Scale) — Functional impairment measure used as a secondary endpoint
How iNGENū runs social anxiety disorder trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Social Anxiety Disorder clinical trials — FAQs
Which drugs are FDA-approved for social anxiety disorder?
What is the primary endpoint in SAD trials?
Is there an approved rapid, as-needed treatment for social anxiety?
Related
Explore more
Ready to discuss your social anxiety disorder trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal